Senior BOND Product Manager (Global), Leica Biosystems
BIOGRAPHY
OCT 17, 2018 9:00 AM PDT
A comparative study of turnaround times for common hematopathology panels on the Leica Biosystems BOND‑III and the Roche Tissue Diagnostics BenchMark ULTRA instruments.
Speakers
-
Melissa Boyd
Global Support Applications Team Lead, Leica BiosystemsBIOGRAPHY
Event Date & Time
DATE: October 17, 2018
TIME: 09:00am PT, 11:00pm CT, 12:00pm ET
Abstract
Each patient case request can vary in what is required to make a diagnosis by the pathologist.
Many times, the pathologist must order a series of tests with multiple antibodies and slides
grouped into what are commonly called panels. Typically, a pathologist needs to review all slides
from a panel to sign out a report from a patient case. Rapid case reporting is crucial in permitting
clinicians to quickly provide patients with certainty, and to triage them to the most appropriate
therapy.
Many times, the pathologist must order a series of tests with multiple antibodies and slides
grouped into what are commonly called panels. Typically, a pathologist needs to review all slides
from a panel to sign out a report from a patient case. Rapid case reporting is crucial in permitting
clinicians to quickly provide patients with certainty, and to triage them to the most appropriate
therapy.
This study compares the turnaround times of 10 common hematopathology panels for two
leading immunohistochemistry slide staining systems – the Leica Biosystems BOND‑III and the
Roche Tissue Diagnostics BenchMark ULTRA.
Panel turnaround times were measured by the difference between the first slide starting
processing and the last slide completing processing on each instrument. Slide processing
times were analyzed for 24 different antibodies across 10 different hematopathology panels
comprising a total of 88 slides. The instruments were operated at full capacity (up to 30 slides
per instrument) and the panels spread over three separate runs. The testing was performed in
triplicate over three days per platform with a total of 264 slide processed on each instrument.
Ready-to-use antibody protocols were used on each instrument where available.
The study demonstrated that across all 10 panels, the BOND-III had a mean speed advantage of
1.43 hours over the BenchMark ULTRA. Overall, BOND-III had an average panel turnaround
time of 2hr 33m whereas the BenchMark ULTRA had an average panel turnaround time of
3hr 59m.
You May Also Like
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 17, 2018 9:00 AM PDT
Share
A comparative study of turnaround times for common hematopathology panels on the Leica Biosystems BOND‑III and the Roche Tissue Diagnostics BenchMark ULTRA instruments.
Loading Comments...